{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:38:53Z","timestamp":1789040333033,"version":"build-2803163510"},"reference-count":264,"publisher":"Springer Science and Business Media LLC","issue":"27","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,7,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prostate cancer is a common cancer in males and there is an urgent unmet clinical need to improve early diagnosis and identify new treatments for advanced disease. Despite huge progress in understanding changes to the genome and proteome in prostate cancer, there is a relative delay in revealing the full aspects of the prostate cancer glycome and glycoproteome. Glycobiology has been fundamental in recent discoveries in the medical field, including translational cancer research. Glycans functionally contribute to the cancer hallmarks and serve as important diagnostic biomarkers and targets for therapeutic intervention. Changes to glycans are common in prostate cancer and include increased branching of complex\n                    <jats:italic>N-<\/jats:italic>\n                    glycans, changes in sialylation, increased fucosylation, altered PSA glycosylation and the expression of truncated\n                    <jats:italic>O-<\/jats:italic>\n                    glycans. This review discusses the role of glycans in fundamental mechanisms controlling prostate cancer growth, metastasis and immune evasion. Emphasis is placed on discoveries made during the last decade, including new insights provided by\n                    <jats:italic>N-<\/jats:italic>\n                    glycan imaging mass spectrometry (IMS) profiling of prostate cancer tissues, new discoveries into the role of aberrant glycosylation in prostate tumour biology, as well as recent studies investigating glycans, glycosyltransferase enzymes and glycan binding proteins as therapeutic targets.\n                  <\/jats:p>","DOI":"10.1038\/s41388-026-03858-x","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:33:53Z","timestamp":1781796833000},"page":"2655-2670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The glycobiology of prostate cancer: an update"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4348-0430","authenticated-orcid":false,"given":"Kirsty","family":"Hodgson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Orozco-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libby","family":"Blencoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3351-0148","authenticated-orcid":false,"given":"Molly J.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Grimsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Beatson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6285-6440","authenticated-orcid":false,"given":"Richard R.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-4531","authenticated-orcid":false,"given":"Jennifer","family":"Munkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"3858_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3858_CR2","doi-asserted-by":"publisher","first-page":"e000643","DOI":"10.1136\/bmjonc-2024-000643","volume":"4","author":"J Dodkins","year":"2025","unstructured":"Dodkins J, Cook A, Mayne E, Parry M, Nossiter J, Payne H, et al. Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation. BMJ Oncol. 2025;4:e000643.","journal-title":"BMJ Oncol"},{"key":"3858_CR3","first-page":"485","volume":"75","author":"TB Kratzer","year":"2025","unstructured":"Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL. Prostate cancer statistics, 2025. CA: A Cancer J Clin. 2025;75:485\u201397.","journal-title":"CA: A Cancer J Clin"},{"key":"3858_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","volume":"36","author":"MH Tan","year":"2015","unstructured":"Tan MH, Li J, Xu HE, Melcher K, Yong EL. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharm Sin. 2015;36:3\u201323.","journal-title":"Acta Pharm Sin"},{"key":"3858_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","volume":"73","author":"S Gillessen","year":"2018","unstructured":"Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol. 2018;73:178\u2013211.","journal-title":"Eur Urol"},{"key":"3858_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"3858_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"3858_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399.","journal-title":"Annu Rev Med"},{"key":"3858_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41392-024-01886-1","volume":"9","author":"M He","year":"2024","unstructured":"He M, Zhou X, Wang X. Glycosylation: mechanisms, biological functions and clinical implications. Signal Transduct Target Ther. 2024;9:194.","journal-title":"Signal Transduct Target Ther"},{"key":"3858_CR10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540\u201355.","journal-title":"Nat Rev Cancer"},{"key":"3858_CR11","unstructured":"Varki A, Kannagi R, Toole B, Stanley P. Glycosylation changes in cancer. In: Varki A, Cummings RD,Esko JD, Stanley P, Hart GW, Aebi M et al. (eds). Essentials of Glycobiology, 3rd edn. 2015. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press 2015."},{"key":"3858_CR12","doi-asserted-by":"publisher","first-page":"35478","DOI":"10.18632\/oncotarget.8155","volume":"7","author":"J Munkley","year":"2016","unstructured":"Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. Oncotarget. 2016;7:35478\u201389.","journal-title":"Oncotarget"},{"key":"3858_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/glycob\/cww086","volume":"27","author":"A Varki","year":"2017","unstructured":"Varki A. Biological roles of glycans. Glycobiology. 2017;27:3\u201349.","journal-title":"Glycobiology"},{"key":"3858_CR14","unstructured":"National Research Council Committee on Assessing the I, Impact of G, Glycosciences. The National Academies Collection: Reports funded by National Institutes of Health. Transforming Glycoscience: A Roadmap for the Future. National Academies Press (US). Copyright \u00a9 2012, National Academy of Sciences: Washington. 2012."},{"key":"3858_CR15","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.cell.2010.11.008","volume":"143","author":"GW Hart","year":"2010","unstructured":"Hart GW, Copeland RJ. Glycomics hits the big time. Cell. 2010;143:672\u20136.","journal-title":"Cell"},{"key":"3858_CR16","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1021\/acschembio.1c00689","volume":"17","author":"D Bojar","year":"2022","unstructured":"Bojar D, Meche L, Meng G, Eng W, Smith DF, Cummings RD, et al. A useful guide to lectin binding: machine-learning directed annotation of 57 unique lectin specificities. ACS Chem Biol. 2022;17:2993\u20133012.","journal-title":"ACS Chem Biol"},{"key":"3858_CR17","doi-asserted-by":"publisher","first-page":"a013359","DOI":"10.1101\/cshperspect.a013359","volume":"5","author":"J Breitling","year":"2013","unstructured":"Breitling J, Aebi M. N-linked protein glycosylation in the endoplasmic reticulum. Cold Spring Harb Perspect Biol. 2013;5:a013359.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3858_CR18","doi-asserted-by":"publisher","first-page":"7183","DOI":"10.1111\/febs.16148","volume":"288","author":"HH Wandall","year":"2021","unstructured":"Wandall HH, Nielsen MAI, King-Smith S, de Haan N, Bagdonaite I. Global functions of O-glycosylation: promises and challenges in O-glycobiology. FEBS J. 2021;288:7183\u2013212.","journal-title":"FEBS J"},{"key":"3858_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189239","volume":"1880","author":"L Eggermont","year":"2025","unstructured":"Eggermont L, Lumen N, Van Praet C, Delanghe J, Rottey S, Vermassen T. A comprehensive view of N-glycosylation as clinical biomarker in prostate cancer. Biochim Biophys Acta Rev Cancer. 2025;1880:189239.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3858_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nrurol.2016.65","volume":"13","author":"J Munkley","year":"2016","unstructured":"Munkley J, Mills IG, Elliott DJ. The role of glycans in the development and progression of prostate cancer. Nat Rev Urol. 2016;13:324\u201333.","journal-title":"Nat Rev Urol"},{"key":"3858_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1155\/2008\/515318","volume":"25","author":"ML de Leoz","year":"2008","unstructured":"de Leoz ML, An HJ, Kronewitter S, Kim J, Beecroft S, Vinall R, et al. Glycomic approach for potential biomarkers on prostate cancer: profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers. 2008;25:243\u201358.","journal-title":"Dis Markers"},{"key":"3858_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/pros.22869","volume":"74","author":"Y Ishibashi","year":"2014","unstructured":"Ishibashi Y, Tobisawa Y, Hatakeyama S, Ohashi T, Tanaka M, Narita S, et al. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant. Prostate Cancer. 2014;74:1521\u20139.","journal-title":"Prostate Cancer"},{"key":"3858_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53384-y","volume":"9","author":"T Matsumoto","year":"2019","unstructured":"Matsumoto T, Hatakeyama S, Yoneyama T, Tobisawa Y, Ishibashi Y, Yamamoto H, et al. Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer. Sci Rep. 2019;9:16761.","journal-title":"Sci Rep"},{"key":"3858_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107471","volume":"300","author":"Y Kizuka","year":"2024","unstructured":"Kizuka Y. Regulation of intracellular activity of N-glycan branching enzymes in mammals. J Biol Chem. 2024;300:107471.","journal-title":"J Biol Chem"},{"key":"3858_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2024.130709","volume":"1868","author":"RF Osuka","year":"2024","unstructured":"Osuka RF, Yamasaki T, Kizuka Y. Structure and function of N-acetylglucosaminyltransferase V (GnT-V). Biochim Biophys Acta Gen Subj. 2024;1868:130709.","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"3858_CR26","first-page":"1993","volume":"28","author":"KH Tsui","year":"2008","unstructured":"Tsui KH, Chang PL, Feng TH, Chung LC, Sung HC, Juang HH. Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis. Anticancer Res. 2008;28:1993\u20139.","journal-title":"Anticancer Res"},{"key":"3858_CR27","doi-asserted-by":"publisher","first-page":"8184.","DOI":"10.3390\/ijms23158184","volume":"23","author":"E Scott","year":"2022","unstructured":"Scott E, Garnham R, Cheung K, Duxfield A, Elliott DJ, Munkley J. Pro-survival factor EDEM3 conferstherapy resistance in prostate cancer. Int J Mol Sci. 2022;23:8184.","journal-title":"Int J Mol Sci"},{"key":"3858_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/COC.0000000000001215","volume":"48","author":"A Sabbah","year":"2025","unstructured":"Sabbah A, Delouya G, Laskine M, Taussky D. Metabolic plasticity in prostate cancer: the warburg effect and its clinical relevance. Am J Clin Oncol. 2025;48:566\u201371.","journal-title":"Am J Clin Oncol"},{"key":"3858_CR29","doi-asserted-by":"publisher","first-page":"55.","DOI":"10.1038\/s41536-021-00163-x","volume":"6","author":"JW Sinclair","year":"2021","unstructured":"Sinclair JW, Hoying DR, Bresciani E, Nogare DD, Needle CD, Berger A. The Warburg effect is necessary to promote glycosylation in the blastema during zebrafish tail regeneration. NPJ Regen Med. 2021;6:55.","journal-title":"NPJ Regen Med"},{"key":"3858_CR30","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1158\/2326-6066.CIR-25-0313","volume":"13","author":"CM Azevedo","year":"2025","unstructured":"Azevedo CM, Xie B, Gunn WG, Peralta RM, Dantas CS, Fernandes-Mendes H, et al. Reprogramming CD8+ T-cell branched N-glycosylation limits exhaustion, enhancing cytotoxicity and tumor killing. Cancer Immunol Res. 2025;13:1655\u201373.","journal-title":"Cancer Immunol Res"},{"key":"3858_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/mas.21725","volume":"42","author":"CT McDowell","year":"2023","unstructured":"McDowell CT, Lu X, Mehta AS, Angel PM, Drake RR. Applications and continued evolution of glycan imaging mass spectrometry. Mass Spectrom Rev. 2023;42:674\u2013705.","journal-title":"Mass Spectrom Rev"},{"key":"3858_CR32","doi-asserted-by":"publisher","first-page":"e106255","DOI":"10.1371\/journal.pone.0106255","volume":"9","author":"TW Powers","year":"2014","unstructured":"Powers TW, Neely BA, Shao Y, Tang H, Troyer DA, Mehta AS, et al. MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin-embedded clinical tissue blocks and tissue microarrays. PLoS One. 2014;9:e106255.","journal-title":"PLoS One"},{"key":"3858_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/cpps.68","volume":"94","author":"RR Drake","year":"2018","unstructured":"Drake RR, Powers TW, Norris-Caneda K, Mehta AS, Angel PM. In situ imaging of N-Glycans by MALDI imaging mass spectrometry of fresh or formalin-fixed paraffin-embedded tissue. Curr Protoc Protein Sci. 2018;94:e68.","journal-title":"Curr Protoc Protein Sci"},{"key":"3858_CR34","doi-asserted-by":"publisher","first-page":"117344.","DOI":"10.1016\/j.trac.2023.117344","volume":"169","author":"KV Djambazova","year":"2023","unstructured":"Djambazova KV, van Ardenne JM, Spraggins JM. Advances in imaging mass spectrometry for biomedical and clinical research. Trends Analyt Chem. 2023;169:117344.","journal-title":"Trends Analyt Chem"},{"key":"3858_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00363-2","volume":"7","author":"W Butler","year":"2023","unstructured":"Butler W, McDowell C, Yang Q, He Y, Zhao Y, Hauck JS, et al. Rewiring of the N-Glycome with prostate cancer progression and therapy resistance. NPJ Precis Oncol. 2023;7:22.","journal-title":"NPJ Precis Oncol"},{"key":"3858_CR36","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/2767-9764.CRC-24-0152","volume":"4","author":"JP Hartig","year":"2024","unstructured":"Hartig JP, Bejar K, Young LEA, Grimsley G, Bethard JR, Troyer DA, et al. Determining the N-glycan and collagen\/extracellular matrix protein compositions in a novel outcome cohort of prostate cancer tissue microarrays using MALDI-MSI. Cancer Res Commun. 2024;4:3036\u201348.","journal-title":"Cancer Res Commun"},{"key":"3858_CR37","doi-asserted-by":"publisher","first-page":"868","DOI":"10.21037\/tau-23-541","volume":"13","author":"N Artamonova","year":"2024","unstructured":"Artamonova N, Djanani A, Schmiederer A, Pipp I, Comp\u00e9rat E, di Santo G, et al. Small cell neuroendocrine prostate cancer with adenocarcinoma components: case report and literature review. Transl Androl Urol. 2024;13:868\u201378.","journal-title":"Transl Androl Urol"},{"key":"3858_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105400","volume":"299","author":"MF Troncoso","year":"2023","unstructured":"Troncoso MF, Elola MT, Blidner AG, Sarrias L, Espelt MV, Rabinovich GA. The universe of galectin-binding partners and their functions in health and disease. J Biol Chem. 2023;299:105400.","journal-title":"J Biol Chem"},{"key":"3858_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0304-4165(02)00311-2","volume":"1572","author":"J Hirabayashi","year":"2002","unstructured":"Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta. 2002;1572:232\u201354.","journal-title":"Biochim Biophys Acta"},{"key":"3858_CR40","doi-asserted-by":"publisher","first-page":"13333.","DOI":"10.3390\/ijms222413333","volume":"22","author":"K Fujita","year":"2021","unstructured":"Fujita K, Hatano K, Hashimoto M, Tomiyama E, Miyoshi E, Nonomura N. Fucosylation in urological cancers. Int J Mol Sci. 2021;22:13333.","journal-title":"Int J Mol Sci"},{"key":"3858_CR41","doi-asserted-by":"publisher","first-page":"41R","DOI":"10.1093\/glycob\/cwg054","volume":"13","author":"DJ Becker","year":"2003","unstructured":"Becker DJ, Lowe JB. Fucose: biosynthesis and biological function in mammals. Glycobiology. 2003;13:41R\u201353R.","journal-title":"Glycobiology"},{"key":"3858_CR42","doi-asserted-by":"publisher","first-page":"455.","DOI":"10.3390\/ijms22010455","volume":"22","author":"K Bastian","year":"2021","unstructured":"Bastian K, Scott E, Elliott DJ, Munkley J. FUT8 Alpha-(1,6)-Fucosyltransferase in Cancer. Int J Mol Sci. 2021;22:455.","journal-title":"Int J Mol Sci"},{"key":"3858_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.chembiol.2018.02.005","volume":"25","author":"J Li","year":"2018","unstructured":"Li J, Hsu HC, Mountz JD, Allen JG. Unmasking fucosylation: from cell adhesion to immune system regulation and diseases. Cell Chem Biol. 2018;25:499\u2013512.","journal-title":"Cell Chem Biol"},{"key":"3858_CR44","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/jb\/mvn011","volume":"143","author":"E Miyoshi","year":"2008","unstructured":"Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem. 2008;143:725\u20139.","journal-title":"J Biochem"},{"key":"3858_CR45","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1038\/bjc.2013.690","volume":"109","author":"J Li","year":"2013","unstructured":"Li J, Guillebon AD, Hsu JW, Barthel SR, Dimitroff CJ, Lee YF, et al. Human fucosyltransferase 6 enables prostate cancer metastasis to bone. Br J Cancer. 2013;109:3014\u201322.","journal-title":"Br J Cancer"},{"key":"3858_CR46","doi-asserted-by":"publisher","first-page":"19491","DOI":"10.1073\/pnas.0906074106","volume":"106","author":"SR Barthel","year":"2009","unstructured":"Barthel SR, Wiese GK, Cho J, Opperman MJ, Hays DL, Siddiqui J, et al. Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci USA 2009;106:19491\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3858_CR47","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/glycob\/cwad085","volume":"33","author":"M Orozco-Moreno","year":"2023","unstructured":"Orozco-Moreno M, Visser EA, Hodgson K, Hipgrave Ederveen AL, Bastian K, Goode EA, et al. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors. Glycobiology. 2023;33:1155\u201371.","journal-title":"Glycobiology"},{"key":"3858_CR48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1158\/1541-7786.MCR-24-0660","volume":"23","author":"JE Ippolito","year":"2025","unstructured":"Ippolito JE, Hartig JP, Bejar K, Nakhoul H, Sehn JK, Weimholt C, et al. N-linked fucosylated glycans are biomarkers for prostate cancer with a neuroendocrine and metastatic phenotype. Mol Cancer Res. 2025;23:59\u201370.","journal-title":"Mol Cancer Res"},{"key":"3858_CR49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1074-7613(01)00166-2","volume":"15","author":"JW Homeister","year":"2001","unstructured":"Homeister JW, Thall AD, Petryniak B, Mal\u00fd P, Rogers CE, Smith PL, et al. The alpha(1,3)fucosyltransferases FucT-IV and FucT-VII exert collaborative control over selectin-dependent leukocyte recruitment and lymphocyte homing. Immunity. 2001;15:115\u201326.","journal-title":"Immunity"},{"key":"3858_CR50","doi-asserted-by":"publisher","first-page":"6571","DOI":"10.1158\/0008-5472.CAN-03-4038","volume":"64","author":"A Zipin","year":"2004","unstructured":"Zipin A, Israeli-Amit M, Meshel T, Sagi-Assif O, Yron I, Lifshitz V, et al. Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells. Cancer Res. 2004;64:6571\u20138.","journal-title":"Cancer Res"},{"key":"3858_CR51","doi-asserted-by":"publisher","first-page":"1068.","DOI":"10.3390\/ijms25021068","volume":"25","author":"M Shi","year":"2024","unstructured":"Shi M, Nan XR, Liu BQ. The multifaceted role of FUT8 in tumorigenesis: from pathways to potential clinical applications. Int J Mol Sci. 2024;25:1068.","journal-title":"Int J Mol Sci"},{"key":"3858_CR52","doi-asserted-by":"publisher","first-page":"103394.","DOI":"10.1016\/j.drudis.2022.103394","volume":"28","author":"Y Lv","year":"2023","unstructured":"Lv Y, Zhang Z, Tian S, Wang W, Li H. Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors. Drug Discov Today. 2023;28:103394.","journal-title":"Drug Discov Today"},{"key":"3858_CR53","first-page":"87","volume":"6","author":"C Mao","year":"2023","unstructured":"Mao C, Li J, Feng L, Gao W. Beyond antibody fucosylation: alpha-(1,6)-fucosyltransferase (Fut8) as a potential new therapeutic target for cancer immunotherapy. Antib Ther. 2023;6:87\u201396.","journal-title":"Antib Ther"},{"key":"3858_CR54","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/glycob\/cwu051","volume":"24","author":"X Wang","year":"2014","unstructured":"Wang X, Chen J, Li QK, Peskoe SB, Zhang B, Choi C, et al. Overexpression of \u03b1 (1,6) fucosyltransferase associated with aggressive prostate cancer. Glycobiology. 2014;24:935\u201344.","journal-title":"Glycobiology"},{"key":"3858_CR55","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/glycob\/cwq147","volume":"21","author":"R Saldova","year":"2011","unstructured":"Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011;21:195\u2013205.","journal-title":"Glycobiology"},{"key":"3858_CR56","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.7150\/jca.58268","volume":"12","author":"C Liao","year":"2021","unstructured":"Liao C, An J, Yi S, Tan Z, Wang H, Li H, et al. FUT8 and protein core fucosylation in tumours: from diagnosis to treatment. J Cancer. 2021;12:4109\u201320.","journal-title":"J Cancer"},{"key":"3858_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2018.01.040","volume":"480","author":"R Lang","year":"2018","unstructured":"Lang R, Leinenbach A, Karl J, Swiatek-de Lange M, Kobold U, Vogeser M. An endoglycosidase-assisted LC-MS\/MS-based strategy for the analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using prostate-specific antigen (PSA) as example. Clin Chim Acta. 2018;480:1\u20138.","journal-title":"Clin Chim Acta"},{"key":"3858_CR58","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1021\/acs.analchem.7b04281","volume":"90","author":"GSM Kammeijer","year":"2018","unstructured":"Kammeijer GSM, Nouta J, de la Rosette J, de Reijke TM, Wuhrer M. An in-depth glycosylation assay for urinary prostate-specific antigen. Anal Chem. 2018;90:4414\u201321.","journal-title":"Anal Chem"},{"key":"3858_CR59","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1002\/ijc.33517","volume":"148","author":"K Fujita","year":"2021","unstructured":"Fujita K, Hatano K, Tomiyama E, Hayashi Y, Matsushita M, Tsuchiya M, et al. Serum core-type fucosylated prostate-specific antigen index for the detection of high-risk prostate cancer. Int J Cancer. 2021;148:3111\u20138.","journal-title":"Int J Cancer"},{"key":"3858_CR60","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41416-021-01637-x","volume":"126","author":"K Hatano","year":"2022","unstructured":"Hatano K, Yoneyama T, Hatakeyama S, Tomiyama E, Tsuchiya M, Nishimoto M, et al. Simultaneous analysis of serum \u03b12,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer. Br J Cancer. 2022;126:764\u201370.","journal-title":"Br J Cancer"},{"key":"3858_CR61","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrurol.2012.258","volume":"10","author":"S Gilgunn","year":"2013","unstructured":"Gilgunn S, Conroy PJ, Saldova R, Rudd PM, O\u2019Kennedy RJ. Aberrant PSA glycosylation\u2013a sweet predictor of prostate cancer. Nat Rev Urol. 2013;10:99\u2013107.","journal-title":"Nat Rev Urol"},{"key":"3858_CR62","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.7150\/thno.15226","volume":"6","author":"E Llop","year":"2016","unstructured":"Llop E, Ferrer-Batalle M, Barrabes S, Guerrero PE, Ramirez M, Saldova R, et al. Improvement of prostate cancer diagnosis by detecting PSA glycosylation-specific changes. Theranostics. 2016;6:1190\u2013204.","journal-title":"Theranostics"},{"key":"3858_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67545-1","volume":"14","author":"S Halld\u00f3rsson","year":"2024","unstructured":"Halld\u00f3rsson S, Hillringhaus L, Hojer C, Muranyi A, Schraeml M, Lange MS, et al. Development of a first-in-class antibody and a specific assay for \u03b1-1,6-fucosylated prostate-specific antigen. Sci Rep. 2024;14:16512.","journal-title":"Sci Rep"},{"key":"3858_CR64","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/pros.22824","volume":"74","author":"K Fujita","year":"2014","unstructured":"Fujita K, Shimomura M, Uemura M, Nakata W, Sato M, Nagahara A, et al. Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer. Prostate. 2014;74:1052\u20138.","journal-title":"Prostate"},{"key":"3858_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50957-w","volume":"14","author":"EN Wallace","year":"2024","unstructured":"Wallace EN, West CA, McDowell CT, Lu X, Bruner E, Mehta AS, et al. An N-glycome tissue atlas of 15 human normal and cancer tissue types determined by MALDI-imaging mass spectrometry. Sci Rep. 2024;14:489.","journal-title":"Sci Rep"},{"key":"3858_CR66","doi-asserted-by":"publisher","first-page":"27810","DOI":"10.1074\/jbc.271.44.27810","volume":"271","author":"N Uozumi","year":"1996","unstructured":"Uozumi N, Yanagidani S, Miyoshi E, Ihara Y, Sakuma T, Gao CX, et al. Purification and cDNA cloning of porcine brain GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha1\u2013>6fucosyltransferase. J Biol Chem. 1996;271:27810\u20137.","journal-title":"J Biol Chem"},{"key":"3858_CR67","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0304-4165(99)00166-X","volume":"1473","author":"E Miyoshi","year":"1999","unstructured":"Miyoshi E, Noda K, Yamaguchi Y, Inoue S, Ikeda Y, Wang W, et al. The alpha1-6-fucosyltransferase gene and its biological significance. Biochim Biophys Acta. 1999;1473:9\u201320.","journal-title":"Biochim Biophys Acta"},{"key":"3858_CR68","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/glycob\/cwx034","volume":"27","author":"M Schneider","year":"2017","unstructured":"Schneider M, Al-Shareffi E, Haltiwanger RS. Biological functions of fucose in mammals. Glycobiology. 2017;27:601\u201318.","journal-title":"Glycobiology"},{"key":"3858_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14794-z","volume":"11","author":"A Garc\u00eda-Garc\u00eda","year":"2020","unstructured":"Garc\u00eda-Garc\u00eda A, Ceballos-Laita L, Serna S, Artschwager R, Reichardt NC, Corzana F, et al. Structural basis for substrate specificity and catalysis of \u03b11,6-fucosyltransferase. Nat Commun. 2020;11:973.","journal-title":"Nat Commun"},{"key":"3858_CR70","doi-asserted-by":"publisher","first-page":"11064","DOI":"10.1074\/jbc.M116.720789","volume":"291","author":"Q Yang","year":"2016","unstructured":"Yang Q, Wang LX. Mammalian alpha-1,6-Fucosyltransferase (FUT8) Is The Sole Enzyme Responsible For The N-acetylglucosaminyltransferase I-independent core fucosylation of high-mannose N-glycans. J Biol Chem. 2016;291:11064\u201371.","journal-title":"J Biol Chem"},{"key":"3858_CR71","doi-asserted-by":"publisher","first-page":"15791","DOI":"10.1073\/pnas.0507375102","volume":"102","author":"X Wang","year":"2005","unstructured":"Wang X, Inoue S, Gu J, Miyoshi E, Noda K, Li W, et al. Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci USA 2005;102:15791\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3858_CR72","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41391-017-0016-7","volume":"21","author":"N H\u00f6ti","year":"2018","unstructured":"H\u00f6ti N, Yang S, Hu Y, Shah P, Haffner MC, Zhang H. Overexpression of \u03b1 (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells. Prostate Cancer Prostatic Dis. 2018;21:137\u201346.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3858_CR73","doi-asserted-by":"publisher","first-page":"468.","DOI":"10.3390\/cancers12020468","volume":"12","author":"N Hoti","year":"2020","unstructured":"Hoti N, Lih TS, Pan J, Zhou Y, Yang G, Deng A. A comprehensive analysis of FUT8 overexpressing prostate cancer cells reveals the role of EGFR in castration resistance. Cancers. 2020;12:468.","journal-title":"Cancers"},{"key":"3858_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70959","volume":"14","author":"K Bastian","year":"2025","unstructured":"Bastian K, Orozco-Moreno M, Thomas H, Hodgson K, Visser EA, Rossing E, et al. FUT8 is a critical driver of prostate tumour growth and can be targeted using fucosylation inhibitors. Cancer Med. 2025;14:e70959.","journal-title":"Cancer Med"},{"key":"3858_CR75","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.1097\/JS9.0000000000002669","volume":"111","author":"Q Ma","year":"2025","unstructured":"Ma Q, Liu Y, Fan Q, Zhu X, Yang D, Zhao Z. Advances in cancer research on FUT8 molecular mechanisms and clinical applications. Int J Surg. 2025;111:6290\u2013304.","journal-title":"Int J Surg"},{"key":"3858_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22618-x","volume":"12","author":"Y Huang","year":"2021","unstructured":"Huang Y, Zhang HL, Li ZL, Du T, Chen YH, Wang Y, et al. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021;12:2672.","journal-title":"Nat Commun"},{"key":"3858_CR77","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41419-023-06027-0","volume":"14","author":"M Wang","year":"2023","unstructured":"Wang M, Zhang Z, Chen M, Lv Y, Tian S, Meng F, et al. FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer. Cell Death Dis. 2023;14:495.","journal-title":"Cell Death Dis"},{"key":"3858_CR78","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/eji.202048543","volume":"50","author":"N Zhang","year":"2020","unstructured":"Zhang N, Li M, Xu X, Zhang Y, Liu Y, Zhao M, et al. Loss of core fucosylation enhances the anticancer activity of cytotoxic T lymphocytes by increasing PD-1 degradation. Eur J Immunol. 2020;50:1820\u201333.","journal-title":"Eur J Immunol"},{"key":"3858_CR79","doi-asserted-by":"publisher","first-page":"3726.","DOI":"10.3390\/cancers13153726","volume":"13","author":"A Ka\u0142u\u017ca","year":"2021","unstructured":"Ka\u0142u\u017ca A, Szczykutowicz J, Ferens-Sieczkowska M. Glycosylation: rising potential for prostate cancer evaluation. Cancers. 2021;13:3726.","journal-title":"Cancers"},{"key":"3858_CR80","first-page":"1817","volume":"55","author":"T J\u00f8rgensen","year":"1995","unstructured":"J\u00f8rgensen T, Berner A, Kaalhus O, Tveter KJ, Danielsen HE, Bryne M. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. Cancer Res. 1995;55:1817\u201319.","journal-title":"Cancer Res"},{"key":"3858_CR81","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/(SICI)1097-0045(19980801)36:3<162::AID-PROS3>3.0.CO;2-J","volume":"36","author":"Z Culig","year":"1998","unstructured":"Culig Z, Hittmair A, Hobisch A, Bartsch G, Klocker H, Pai LH, et al. Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma. Prostate. 1998;36:162\u201367.","journal-title":"Prostate"},{"key":"3858_CR82","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/0046-8177(95)90220-1","volume":"26","author":"S M\u00e5rtensson","year":"1995","unstructured":"M\u00e5rtensson S, Bigler SA, Brown M, Lange PH, Brawer MK, Hakomori S. Sialyl-Lewis(x) and related carbohydrate antigens in the prostate. Hum Pathol. 1995;26:735\u201339.","journal-title":"Hum Pathol"},{"key":"3858_CR83","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/ajcp\/81.4.503","volume":"81","author":"PD Walker","year":"1984","unstructured":"Walker PD, Karnik S, deKernion JB, Pramberg JC. Cell surface blood group antigens in prostatic carcinoma. Am J Clin Pathol. 1984;81:503\u2013506.","journal-title":"Am J Clin Pathol"},{"key":"3858_CR84","first-page":"578","volume":"131","author":"WW Young Jr.","year":"1988","unstructured":"Young WW Jr., Mills SE, Lippert MC, Ahmed P, Lau SK. Deletion of antigens of the Lewis a\/b blood group family in human prostatic carcinoma. Am J Pathol. 1988;131:578\u201386.","journal-title":"Am J Pathol"},{"key":"3858_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.809170","volume":"11","author":"W Butler","year":"2021","unstructured":"Butler W, Huang J. Glycosylation changes in prostate cancer progression. Front Oncol. 2021;11:809170.","journal-title":"Front Oncol"},{"key":"3858_CR86","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/path.6152","volume":"261","author":"E Scott","year":"2023","unstructured":"Scott E, Archer Goode E, Garnham R, Hodgson K, Orozco-Moreno M, Turner H, et al. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression. J Pathol. 2023;261:71\u201384.","journal-title":"J Pathol"},{"key":"3858_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/ansa.70016","volume":"6","author":"YT Ngai","year":"2025","unstructured":"Ngai YT, Lau D, Mittal P, Hoffmann P. Mini review: highlights of recent advances and applications of MALDI mass spectrometry imaging in 2024. Anal Sci Adv. 2025;6:e70016.","journal-title":"Anal Sci Adv"},{"key":"3858_CR88","doi-asserted-by":"publisher","first-page":"7475","DOI":"10.1021\/acs.analchem.2c04882","volume":"95","author":"X Lu","year":"2023","unstructured":"Lu X, McDowell CT, Blaschke CRK, Liu L, Grimsley G, Wisniewski L, et al. Bioorthogonal chemical labeling probes targeting sialic acid isomers for N-glycan MALDI imaging mass spectrometry of tissues, cells, and biofluids. Anal Chem. 2023;95:7475\u201386.","journal-title":"Anal Chem"},{"key":"3858_CR89","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/1538-7445.AM2025-766","volume":"85","author":"K Rashford","year":"2025","unstructured":"Rashford K, Kittrell C, Drake BF, Ahmed A, Klim A, Kim E, et al. Abstract 766: Spatial evaluation of tumor sialylation of N-linked glycans in prostate cancer tissues. Cancer Res. 2025;85:766\u2013766.","journal-title":"Cancer Res"},{"key":"3858_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105163","volume":"104","author":"K Hodgson","year":"2024","unstructured":"Hodgson K, Orozco-Moreno M, Goode EA, Fisher M, Garnham R, Beatson R, et al. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone. EBioMedicine. 2024;104:105163.","journal-title":"EBioMedicine"},{"key":"3858_CR91","doi-asserted-by":"publisher","first-page":"2528.","DOI":"10.3390\/ijms20102528","volume":"20","author":"H Herrera","year":"2019","unstructured":"Herrera H, Dilday T, Uber A, Scott D, Zambrano JN, Wang M. Core-fucosylated tetra-antennary N-glycan containing a single N-acetyllactosamine branch is associated with poor survival outcome in breast cancer. Int J Mol Sci. 2019;20:2528.","journal-title":"Int J Mol Sci"},{"key":"3858_CR92","first-page":"983","volume":"18","author":"R Garnham","year":"2019","unstructured":"Garnham R, Scott E, Livermore KE, Munkley J. ST6GAL1: a key player in cancer. Oncol Lett. 2019;18:983\u20139.","journal-title":"Oncol Lett"},{"key":"3858_CR93","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41416-020-01126-7","volume":"124","author":"C Dobie","year":"2021","unstructured":"Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. Br J Cancer. 2021;124:76\u201390.","journal-title":"Br J Cancer"},{"key":"3858_CR94","doi-asserted-by":"publisher","first-page":"e161563.","DOI":"10.1172\/jci.insight.161563","volume":"8","author":"N Bhalerao","year":"2023","unstructured":"Bhalerao N, Chakraborty A, Marciel MP, Hwang J, Britain CM, Silva AD. ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression. JCI Insight. 2023;8:e161563.","journal-title":"JCI Insight"},{"key":"3858_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406225","volume":"12","author":"X Xu","year":"2025","unstructured":"Xu X, Liu J, Qin W, Ding C, Cai Z, Shu D, et al. ST6GAL1-mediated sialylation stabilizes PD-L1 and drives immunosuppressive tumor microenvironment in colorectal cancer. Adv Sci. 2025;12:e06225.","journal-title":"Adv Sci"},{"key":"3858_CR96","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/glycob\/cwad051","volume":"33","author":"RB Jones","year":"2023","unstructured":"Jones RB, Silva AD, Ankenbauer KE, Britain CM, Chakraborty A, Brown JA, et al. Role of the ST6GAL1 sialyltransferase in regulating ovarian cancer cell metabolism. Glycobiology. 2023;33:626\u201336.","journal-title":"Glycobiology"},{"key":"3858_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107752","volume":"300","author":"AD Silva","year":"2024","unstructured":"Silva AD, Hwang J, Marciel MP, Bellis SL. The pro-inflammatory cytokines IL-1\u03b2 and IL-6 promote upregulation of the ST6GAL1 sialyltransferase in pancreatic cancer cells. J Biol Chem. 2024;300:107752.","journal-title":"J Biol Chem"},{"key":"3858_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2021.100160","volume":"20","author":"E Kurz","year":"2021","unstructured":"Kurz E, Chen S, Vucic E, Baptiste G, Loomis C, Agrawal P, et al. Integrated systems analysis of the murine and human pancreatic cancer glycomes reveals a tumor-promoting role for ST6GAL1. Mol Cell Proteom. 2021;20:100160.","journal-title":"Mol Cell Proteom"},{"key":"3858_CR99","doi-asserted-by":"publisher","first-page":"65374","DOI":"10.18632\/oncotarget.11699","volume":"7","author":"A Wei","year":"2016","unstructured":"Wei A, Fan B, Zhao Y, Zhang H, Wang L, Yu X, et al. ST6Gal-I overexpression facilitates prostate cancer progression via the PI3K\/Akt\/GSK-3\u03b2\/\u03b2-catenin signaling pathway. Oncotarget. 2016;7:65374\u201388.","journal-title":"Oncotarget"},{"key":"3858_CR100","doi-asserted-by":"publisher","first-page":"2953.","DOI":"10.3390\/cancers16172953","volume":"16","author":"EA Goode","year":"2024","unstructured":"Goode EA, Orozco-Moreno M, Hodgson K, Nabilah A, Murali M, Peng Z, et al. Sialylation inhibition can partially revert acquired resistance to enzalutamide in prostate cancer cells. Cancers. 2024;16:2953.","journal-title":"Cancers"},{"key":"3858_CR101","doi-asserted-by":"publisher","first-page":"e0329014","DOI":"10.1371\/journal.pone.0329014","volume":"20","author":"CA Bach","year":"2025","unstructured":"Bach CA, Hossain MN, Chaudhari IJ, Verrillo CE, Naranjo NM, Amoroso I, et al. A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer. PLoS One. 2025;20:e0329014.","journal-title":"PLoS One"},{"key":"3858_CR102","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrc2351","volume":"8","author":"H Lilja","year":"2008","unstructured":"Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268\u201378.","journal-title":"Nat Rev Cancer"},{"key":"3858_CR103","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. Bmj. 2018;362:k3519.","journal-title":"Bmj"},{"key":"3858_CR104","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.urolonc.2024.06.003","volume":"43","author":"VM Sundaresan","year":"2025","unstructured":"Sundaresan VM, Smani S, Rajwa P, Renzulli J, Sprenkle PC, Kim IY, et al. Prostate-specific antigen screening for prostate cancer: diagnostic performance, clinical thresholds, and strategies for refinement. Urol Oncol. 2025;43:41\u201348.","journal-title":"Urol Oncol"},{"key":"3858_CR105","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/MOU.0000000000000316","volume":"26","author":"S Loeb","year":"2016","unstructured":"Loeb S, Lilja H, Vickers A. Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol. 2016;26:459\u201365.","journal-title":"Curr Opin Urol"},{"key":"3858_CR106","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/glycob\/cwh071","volume":"14","author":"C Ohyama","year":"2004","unstructured":"Ohyama C, Hosono M, Nitta K, Oh-eda M, Yoshikawa K, Habuchi T, et al. Carbohydrate structure and differential binding of prostate-specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology. 2004;14:671\u20139.","journal-title":"Glycobiology"},{"key":"3858_CR107","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1373\/clinchem.2018.295790","volume":"65","author":"S Srinivasan","year":"2019","unstructured":"Srinivasan S, Stephens C, Wilson E, Panchadsaram J, DeVoss K, Koistinen H, et al. prostate cancer risk-associated single-nucleotide polymorphism affects prostate-specific antigen glycosylation and its function. Clin Chem. 2019;65:e1\u2013e9.","journal-title":"Clin Chem"},{"key":"3858_CR108","first-page":"1","volume":"161","author":"J Hartig","year":"2024","unstructured":"Hartig J, Young LEA, Grimsley G, Mehta AS, Ippolito JE, Leach RJ, et al. The glycosylation landscape of prostate cancer tissues and biofluids. Adv Cancer Res. 2024;161:1\u201330.","journal-title":"Adv Cancer Res"},{"key":"3858_CR109","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.21037\/tau-20-964","volume":"10","author":"S Hatakeyama","year":"2021","unstructured":"Hatakeyama S, Yoneyama T, Tobisawa Y, Yamamoto H, Ohyama C. Narrative review of urinary glycan biomarkers in prostate cancer. Transl Androl Urol. 2021;10:1850\u201364.","journal-title":"Transl Androl Urol"},{"key":"3858_CR110","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.cca.2010.08.009","volume":"411","author":"MV Dwek","year":"2010","unstructured":"Dwek MV, Jenks A, Leathem AJ. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate-specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clin Chim Acta. 2010;411:1935\u20139.","journal-title":"Clin Chim Acta"},{"key":"3858_CR111","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/glycob\/cwg041","volume":"13","author":"R Peracaula","year":"2003","unstructured":"Peracaula R, Tabar\u00e9s G, Royle L, Harvey DJ, Dwek RA, Rudd PM, et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology. 2003;13:457\u201370.","journal-title":"Glycobiology"},{"key":"3858_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116156","volume":"39","author":"A Bertokova","year":"2021","unstructured":"Bertokova A, Bertok T, Jane E, Hires M, \u010eubjakov\u00e1 P, Novotn\u00e1 O, et al. Detection of N,N-diacetyllactosamine (LacdiNAc) containing free prostate-specific antigen for early stage prostate cancer diagnostics and for identification of castration-resistant prostate cancer patients. Bioorg Med Chem. 2021;39:116156.","journal-title":"Bioorg Med Chem"},{"key":"3858_CR113","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/pros.70014","volume":"85","author":"H Koistinen","year":"2025","unstructured":"Koistinen H, Merivirta RM, Lehto TP, Lempiainen A, Erickson A, Stenman UH, et al. Altered glycosylation of PSA in prostate cancer tissue. Prostate. 2025;85:1290\u20138.","journal-title":"Prostate"},{"key":"3858_CR114","doi-asserted-by":"publisher","first-page":"e0300430","DOI":"10.1371\/journal.pone.0300430","volume":"19","author":"A Pinkeova","year":"2024","unstructured":"Pinkeova A, Tomikova A, Bertokova A, Fabinyova E, Bartova R, Jane E, et al. Glycoprofiling of proteins as prostate cancer biomarkers: a multinational population study. PLoS One. 2024;19:e0300430.","journal-title":"PLoS One"},{"key":"3858_CR115","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4062\/biomolther.2012.095","volume":"21","author":"HY Kong","year":"2013","unstructured":"Kong HY, Byun J. Emerging roles of human prostatic acid phosphatase. Biomol Ther (Seoul). 2013;21:10\u201320.","journal-title":"Biomol Ther (Seoul)"},{"key":"3858_CR116","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/0167-4781(90)90024-V","volume":"1048","author":"T Solin","year":"1990","unstructured":"Solin T, Kontturi M, Pohlmann R, Vihko P. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses. Biochim Biophys Acta. 1990;1048:72\u20137.","journal-title":"Biochim Biophys Acta"},{"key":"3858_CR117","doi-asserted-by":"publisher","first-page":"e32741","DOI":"10.1371\/journal.pone.0032741","volume":"7","author":"JK Hurt","year":"2012","unstructured":"Hurt JK, Fitzpatrick BJ, Norris-Drouin J, Zylka MJ. Secretion and N-linked glycosylation are required for prostatic acid phosphatase catalytic and antinociceptive activity. PLoS One. 2012;7:e32741.","journal-title":"PLoS One"},{"key":"3858_CR118","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1021\/acsmeasuresciau.3c00055","volume":"4","author":"W Wang","year":"2024","unstructured":"Wang W, de Nier CR, Wuhrer M, Lageveen-Kammeijer GSM. In-depth glycoproteomic assay of urinary prostatic acid phosphatase. ACS Meas Sci Au. 2024;4:117\u201326.","journal-title":"ACS Meas Sci Au"},{"key":"3858_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95417-5","volume":"11","author":"S Sug\u00e1r","year":"2021","unstructured":"Sug\u00e1r S, T\u00f3th G, Bugyi F, V\u00e9key K, Kar\u00e1szi K, Drahos L, et al. Alterations in protein expression and site-specific N-glycosylation of prostate cancer tissues. Sci Rep. 2021;11:15886.","journal-title":"Sci Rep"},{"key":"3858_CR120","first-page":"S13","volume":"6 Suppl 10","author":"SS Chang","year":"2004","unstructured":"Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6 Suppl 10:S13\u201318.","journal-title":"Rev Urol"},{"key":"3858_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01590-w","volume":"28","author":"H Zhang","year":"2023","unstructured":"Zhang H, Xiao L, Xie H, Li L. Hotspots and frontiers in PSMA research for prostate cancer: a bibliometric and visualization analysis over the past 20 years. Eur J Med Res. 2023;28:610.","journal-title":"Eur J Med Res"},{"key":"3858_CR122","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.3390\/cancers16244263","volume":"16","author":"F von Stauffenberg","year":"2024","unstructured":"von Stauffenberg F, Poyet C, Beintner-Skawran S, Maurer A, Schmid FA. Current clinical applications of PSMA-PET for prostate cancer diagnosis, staging, and treatment. Cancers. 2024;16:4263.","journal-title":"Cancers"},{"key":"3858_CR123","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s12094-022-02983-9","volume":"25","author":"C-B Wang","year":"2023","unstructured":"Wang C-B, Chen S-H, Zhao L, Jin X, Chen X, Ji J, et al. Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy. Clin Transl Oncol. 2023;25:758\u201367.","journal-title":"Clin Transl Oncol"},{"key":"3858_CR124","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.3390\/cancers14122987","volume":"14","author":"S Allelein","year":"2022","unstructured":"Allelein S, Aerchlimann K, Roesch G, Khajehamiri R, Koelsch A, Freese C, et al. Prostate-specific membrane antigen (PSMA)-positive extracellular vesicles in urine\u2014a potential liquid biopsy strategy for prostate cancer diagnosis? Cancers. 2022;14:2987.","journal-title":"Cancers"},{"key":"3858_CR125","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/pros.24666","volume":"84","author":"S Mackay","year":"2024","unstructured":"Mackay S, Oduor IO, Burch TC, Troyer DA, Semmes OJ, Nyalwidhe JO. Prostate-specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma. Prostate. 2024;84:479\u201390.","journal-title":"Prostate"},{"key":"3858_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.142238","volume":"307","author":"Y Shi","year":"2025","unstructured":"Shi Y, Shi M, Du W, Zhang Y, Li B, Zhang T, et al. Increased N-glycosylation of PSMA by GnT-V enhances tumor malignancy through interacting with JAK2 and the subsequent STAT3-mediated transcriptional activation in prostate cancer. Int J Biol Macromol. 2025;307:142238.","journal-title":"Int J Biol Macromol"},{"key":"3858_CR127","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/pros.24254","volume":"82","author":"W Yuan","year":"2022","unstructured":"Yuan W, Liu B, Sanda M, Wei R, Benicky J, Novakova Z, et al. Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue. Prostate. 2022;82:132\u201344.","journal-title":"Prostate"},{"key":"3858_CR128","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/pros.24724","volume":"84","author":"S Mackay","year":"2024","unstructured":"Mackay S, Oduor IO, Burch TC, Main BP, Troyer DA, Semmes OJ, et al. Increased \u03b12, 3-sialyl N-glycosylated prostate-specific membrane antigen (PSMA) in post-DRE urine is associated with high-grade group prostate cancer. Prostate. 2024;84:1067\u201375.","journal-title":"Prostate"},{"key":"3858_CR129","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/pros.22918","volume":"75","author":"T Vermassen","year":"2015","unstructured":"Vermassen T, Van Praet C, Lumen N, Decaestecker K, Vanderschaeghe D, Callewaert N, et al. Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancer. prostate. 2015;75:314\u201322.","journal-title":"prostate"},{"key":"3858_CR130","doi-asserted-by":"publisher","first-page":"120790.","DOI":"10.1016\/j.cca.2025.120790","volume":"582","author":"M Khan","year":"2025","unstructured":"Khan M, Islam MK, Taimen P, Bostr\u00f6m PJ, Lamminm\u00e4ki U, Leivo J. Aberrantly glycosylated PSMA in urine as a potential marker for prostate cancer. Clin Chim Acta. 2025;582:120790.","journal-title":"Clin Chim Acta"},{"key":"3858_CR131","doi-asserted-by":"publisher","first-page":"6257.","DOI":"10.1038\/s41467-022-33806-8","volume":"13","author":"MI Nielsen","year":"2022","unstructured":"Nielsen MI, de Haan N, Kightlinger W, Ye Z, Dabelsteen S, Li M. Global mapping of GalNAc-T isoform-specificities and O-glycosylation site-occupancy in a tissue-forming human cell line. Nat Commun. 2022;13:6257.","journal-title":"Nat Commun"},{"key":"3858_CR132","doi-asserted-by":"publisher","first-page":"394.","DOI":"10.3390\/cells13050394","volume":"13","author":"A Helms","year":"2024","unstructured":"Helms A, Brodbelt JS. Mass spectrometry strategies for O-glycoproteomics. Cells. 2024;13:394.","journal-title":"Cells"},{"key":"3858_CR133","doi-asserted-by":"publisher","first-page":"12.","DOI":"10.1186\/s13045-024-01532-x","volume":"17","author":"K He","year":"2024","unstructured":"He K, Baniasad M, Kwon H, Caval T, Xu G, Lebrilla C. Decoding the glycoproteome: a new frontier for biomarker discovery in cancer. J Hematol Oncol. 2024;17:12.","journal-title":"J Hematol Oncol"},{"key":"3858_CR134","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA120.002320","volume":"20","author":"R Kawahara","year":"2021","unstructured":"Kawahara R, Recuero S, Srougi M, Leite KRM, Thaysen-Andersen M, Palmisano G. The complexity and dynamics of the tissue glycoproteome associated with prostate cancer progression. Mol Cell Proteom. 2021;20:100026.","journal-title":"Mol Cell Proteom"},{"key":"3858_CR135","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3892\/mmr.2012.1189","volume":"7","author":"T Okamoto","year":"2013","unstructured":"Okamoto T, Yoneyama MS, Hatakeyama S, Mori K, Yamamoto H, Koie T, et al. Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity. Mol Med Rep. 2013;7:359\u201364.","journal-title":"Mol Med Rep"},{"key":"3858_CR136","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0304-4165(99)00170-1","volume":"1473","author":"I Brockhausen","year":"1999","unstructured":"Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta. 1999;1473:67\u201395.","journal-title":"Biochim Biophys Acta"},{"key":"3858_CR137","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41388-023-02604-x","volume":"42","author":"E Scott","year":"2023","unstructured":"Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, et al. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene. 2023;42:926\u201337.","journal-title":"Oncogene"},{"key":"3858_CR138","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/ijms17030275","volume":"17","author":"J Munkley","year":"2016","unstructured":"Munkley J. The role of Sialyl-Tn in cancer. Int J Mol Sci. 2016;17:275.","journal-title":"Int J Mol Sci"},{"key":"3858_CR139","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/1535-7163.MCT-08-0934","volume":"8","author":"Q Li","year":"2009","unstructured":"Li Q, Anver MR, Butcher DO, Gildersleeve JC. Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines. Mol Cancer Ther. 2009;8:971\u201379.","journal-title":"Mol Cancer Ther"},{"key":"3858_CR140","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70279","volume":"28","author":"T Du","year":"2024","unstructured":"Du T, Dong X, Tan J, Chen X, Liu J, Wen T, et al. Targeting Tn antigen suppresses aberrant O-glycosylation-elicited metastasis in breast cancer. J Cell Mol Med. 2024;28:e70279.","journal-title":"J Cell Mol Med"},{"key":"3858_CR141","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2021.06.012","volume":"518","author":"V da Costa","year":"2021","unstructured":"da Costa V, van Vliet SJ, Carasi P, Frigerio S, Garc\u00eda PA, Croci DO, et al. The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis via interaction with Macrophage Galactose-type lectin 2 (MGL2). Cancer Lett. 2021;518:72\u201381.","journal-title":"Cancer Lett"},{"key":"3858_CR142","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/biom2040435","volume":"2","author":"S Julien","year":"2012","unstructured":"Julien S, Videira PA, Delannoy P. Sialyl-tn in cancer: (how) did we miss the target? Biomolecules. 2012;2:435\u201366.","journal-title":"Biomolecules"},{"key":"3858_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-21496-3","volume":"15","author":"RA Louren\u00e7o","year":"2025","unstructured":"Louren\u00e7o RA, Barreira DF, Lopes C, Granjo P, Rodrigues AS, Silva Z, et al. Sialyl-Tn expression correlates with reduced c-Myc and immune modulation in triple-negative breast cancer. Sci Rep. 2025;15:37615.","journal-title":"Sci Rep"},{"key":"3858_CR144","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.canlet.2006.08.010","volume":"249","author":"S Pinho","year":"2007","unstructured":"Pinho S, Marcos NT, Ferreira B, Carvalho AS, Oliveira MJ, Santos-Silva F, et al. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett. 2007;249:157\u201370.","journal-title":"Cancer Lett"},{"key":"3858_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102350","volume":"6","author":"R Abrantes","year":"2025","unstructured":"Abrantes R, Forcados C, Warren DJ, Santos-Ferreira L, Fleten KG, Senra E, et al. Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. Cell Rep Med. 2025;6:102350.","journal-title":"Cell Rep Med"},{"key":"3858_CR146","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1074\/jbc.M511826200","volume":"281","author":"R Sewell","year":"2006","unstructured":"Sewell R, B\u00e4ckstr\u00f6m M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, et al. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem. 2006;281:3586\u201394.","journal-title":"J Biol Chem"},{"key":"3858_CR147","doi-asserted-by":"publisher","first-page":"7050","DOI":"10.1158\/0008-5472.CAN-04-1921","volume":"64","author":"NT Marcos","year":"2004","unstructured":"Marcos NT, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin-Lepers A, et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res. 2004;64:7050\u20137.","journal-title":"Cancer Res"},{"key":"3858_CR148","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/glycob\/9.11.1213","volume":"9","author":"Y Ikehara","year":"1999","unstructured":"Ikehara Y, Kojima N, Kurosawa N, Kudo T, Kono M, Nishihara S, et al. Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2,6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens. Glycobiology. 1999;9:1213\u201324.","journal-title":"Glycobiology"},{"key":"3858_CR149","doi-asserted-by":"publisher","first-page":"34358","DOI":"10.18632\/oncotarget.6024","volume":"6","author":"J Munkley","year":"2015","unstructured":"Munkley J, Oltean S, Vodak D, Wilson BT, Livermore KE, Zhou Y, et al. The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget. 2015;6:34358\u201374.","journal-title":"Oncotarget"},{"key":"3858_CR150","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/modpathol.3880220","volume":"13","author":"EM Genega","year":"2000","unstructured":"Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13:1186\u201391.","journal-title":"Mod Pathol"},{"key":"3858_CR151","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0022-5347(17)32870-7","volume":"152","author":"RB Myers","year":"1994","unstructured":"Myers RB, Meredith RF, Schlom J, LoBuglio AF, Bueschen AJ, Wheeler RH, et al. Tumor- associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. J Urol. 1994;152:243\u20136.","journal-title":"J Urol"},{"key":"3858_CR152","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10719-023-10104-z","volume":"40","author":"D Yamamoto","year":"2023","unstructured":"Yamamoto D, Hongo H, Kosaka T, Aoki N, Oya M, Sato T. The sialyl-Tn antigen synthase genes regulates migration-proliferation dichotomy in prostate cancer cells under hypoxia. Glycoconj J. 2023;40:199\u2013212.","journal-title":"Glycoconj J"},{"key":"3858_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1660852","volume":"16","author":"S Zhao","year":"2025","unstructured":"Zhao S, Fu C, Gong B, Wu H, Zhang R, Cai H, et al. Tumor-associated Tn and STn antigens: from molecular mechanism to precision diagnosis and treatment. Front Immunol. 2025;16:1660852.","journal-title":"Front Immunol"},{"key":"3858_CR154","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/glycob\/cws139","volume":"23","author":"R Takamiya","year":"2012","unstructured":"Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-\u03b2 secretion from monocytes\/macrophages through the DAP12\u2013Syk pathway. Glycobiology. 2012;23:178\u201387.","journal-title":"Glycobiology"},{"key":"3858_CR155","doi-asserted-by":"publisher","unstructured":"Peng Z, Hodgson K, Fisher M, Mei S, Orozco-Moreno M, Cao L, et al. Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis. Preprint at https:\/\/doi.org\/10.1101\/2025.11.12.687981 2025.","DOI":"10.1101\/2025.11.12.687981"},{"key":"3858_CR156","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25:656\u201366.","journal-title":"Nat Med"},{"key":"3858_CR157","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312929121","volume":"121","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xu Z, Wu KL, Yu L, Wang C, Ding H, et al. Siglec-15\/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis. Proc Natl Acad Sci USA 2024;121:e2312929121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3858_CR158","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/pros.22826","volume":"74","author":"Z Chen","year":"2014","unstructured":"Chen Z, Gulzar ZG, St Hill CA, Walcheck B, Brooks JD. Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancer. Prostate. 2014;74:1059\u201367.","journal-title":"Prostate"},{"key":"3858_CR159","doi-asserted-by":"publisher","first-page":"e0138520","DOI":"10.1371\/journal.pone.0138520","volume":"10","author":"Y Kojima","year":"2015","unstructured":"Kojima Y, Yoneyama T, Hatakeyama S, Mikami J, Sato T, Mori K, et al. Detection of core2 \u03b2-1,6-N-acetylglucosaminyltransferase in post-digital rectal examination urine is a reliable indicator for extracapsular extension of prostate cancer. PLoS One. 2015;10:e0138520.","journal-title":"PLoS One"},{"key":"3858_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43019-8","volume":"13","author":"K Hodgson","year":"2023","unstructured":"Hodgson K, Orozco-Moreno M, Scott E, Garnham R, Livermore K, Thomas H, et al. The role of GCNT1-mediated O-glycosylation in aggressive prostate cancer. Sci Rep. 2023;13:17031.","journal-title":"Sci Rep"},{"key":"3858_CR161","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbrc.2016.01.011","volume":"470","author":"T Sato","year":"2016","unstructured":"Sato T, Yoneyama T, Tobisawa Y, Hatakeyama S, Yamamoto H, Kojima Y, et al. Core 2 \u03b2-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimens is an indicator of prostate cancer aggressiveness. Biochem Biophys Res Commun. 2016;470:150\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"3858_CR162","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/glycob\/cwi086","volume":"15","author":"S Hagisawa","year":"2005","unstructured":"Hagisawa S, Ohyama C, Takahashi T, Endoh M, Moriya T, Nakayama J, et al. Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. Glycobiology. 2005;15:1016\u201324.","journal-title":"Glycobiology"},{"key":"3858_CR163","doi-asserted-by":"publisher","first-page":"7683","DOI":"10.1158\/0008-5472.CAN-11-1139","volume":"71","author":"S Julien","year":"2011","unstructured":"Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D, et al. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res. 2011;71:7683\u201393.","journal-title":"Cancer Res"},{"key":"3858_CR164","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/glycob\/cwq085","volume":"20","author":"G Picco","year":"2010","unstructured":"Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, Haslam S, et al. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology. 2010;20:1241\u201350.","journal-title":"Glycobiology"},{"key":"3858_CR165","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/glycob\/9.12.1307","volume":"9","author":"J Burchell","year":"1999","unstructured":"Burchell J, Poulsom R, Hanby A, Whitehouse C, Cooper L, Clausen H, et al. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology. 1999;9:1307\u201311.","journal-title":"Glycobiology"},{"key":"3858_CR166","first-page":"fj201800687.","volume":"15","author":"SF Tzeng","year":"2018","unstructured":"Tzeng SF, Tsai CH, Chao TK, Chou YC, Yang YC, Tsai MH. O-Glycosylation-mediated signaling circuit drives metastatic castration-resistant prostate cancer. FASEB J. 2018;15:fj201800687.","journal-title":"FASEB J"},{"key":"3858_CR167","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.1158\/0008-5472.CAN-05-4431","volume":"67","author":"HF Valenzuela","year":"2007","unstructured":"Valenzuela HF, Pace KE, Cabrera PV, White R, Porvari K, Kaija H, et al. O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1. Cancer Res. 2007;67:6155\u201362.","journal-title":"Cancer Res"},{"key":"3858_CR168","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1158\/1541-7786.MCR-14-0291-T","volume":"12","author":"A Petrosyan","year":"2014","unstructured":"Petrosyan A, Holzapfel MS, Muirhead DE, Cheng PW. Restoration of compact Golgi morphology in advanced prostate cancer enhances susceptibility to galectin-1-induced apoptosis by modifying mucin O-glycan synthesis. Mol Cancer Res. 2014;12:1704\u201316.","journal-title":"Mol Cancer Res"},{"key":"3858_CR169","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21550-4","volume":"12","author":"E Rodriguez","year":"2021","unstructured":"Rodriguez E, Boelaars K, Brown K, Eveline Li RJ, Kruijssen L, Bruijns SCM, et al. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat Commun. 2021;12:1270.","journal-title":"Nat Commun"},{"key":"3858_CR170","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s42003-024-05924-0","volume":"7","author":"R Garnham","year":"2024","unstructured":"Garnham R, Geh D, Nelson R, Ramon-Gil E, Wilson L, Schmidt EN, et al. ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer. Commun Biol. 2024;7:276.","journal-title":"Commun Biol"},{"key":"3858_CR171","doi-asserted-by":"publisher","first-page":"e012391.","DOI":"10.1136\/jitc-2025-012391","volume":"13","author":"SS Pinho","year":"2025","unstructured":"Pinho SS, Macauley MS, L\u00e4ubli H. Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy. J Immunother Cancer. 2025;13:e012391.","journal-title":"J Immunother Cancer"},{"key":"3858_CR172","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/glycob\/cwr087","volume":"21","author":"A Varki","year":"2011","unstructured":"Varki A. Since there are PAMPs and DAMPs, there must be SAMPs? Glycan \u2018self-associated molecular patterns\u2019 dampen innate immunity, but pathogens can mimic them. Glycobiology. 2011;21:1121\u201324.","journal-title":"Glycobiology"},{"key":"3858_CR173","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/imm.13494","volume":"168","author":"\u00c2 Fernandes","year":"2023","unstructured":"Fernandes \u00c2, Azevedo CM, Silva MC, Faria G, Dantas CS, Vicente MM, et al. Glycans as shapers of tumour microenvironment: a sweet driver of T-cell-mediated anti-tumour immune response. Immunology. 2023;168:217\u201332.","journal-title":"Immunology"},{"key":"3858_CR174","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/s41423-023-01074-1","volume":"20","author":"SS Pinho","year":"2023","unstructured":"Pinho SS, Alves I, Gaifem J, Rabinovich GA. Immune regulatory networks coordinated by glycans and glycan-binding proteins in autoimmunity and infection. Cell Mol Immunol. 2023;20:1101\u201313.","journal-title":"Cell Mol Immunol"},{"key":"3858_CR175","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/1873-3468.14347","volume":"596","author":"I Alves","year":"2022","unstructured":"Alves I, Fernandes \u00c2, Santos-Pereira B, Azevedo CM, Pinho SS. Glycans as a key factor in self and nonself discrimination: impact on the breach of immune tolerance. FEBS Lett. 2022;596:1485\u2013502.","journal-title":"FEBS Lett"},{"key":"3858_CR176","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/ni.f.203","volume":"9","author":"Y van Kooyk","year":"2008","unstructured":"van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol. 2008;9:593\u2013601.","journal-title":"Nat Immunol"},{"key":"3858_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2022.101112","volume":"90","author":"MA Stanczak","year":"2023","unstructured":"Stanczak MA, L\u00e4ubli H. Siglec receptors as new immune checkpoints in cancer. Mol Asp Med. 2023;90:101112.","journal-title":"Mol Asp Med"},{"key":"3858_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2022.101117","volume":"90","author":"T Angata","year":"2023","unstructured":"Angata T, Varki A. Discovery, classification, evolution and diversity of Siglecs. Mol Asp Med. 2023;90:101117.","journal-title":"Mol Asp Med"},{"key":"3858_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2024.101925","volume":"77","author":"SY Lin","year":"2025","unstructured":"Lin SY, Schmidt EN, Takahashi-Yamashiro K, Macauley MS. Roles for Siglec-glycan interactions in regulating immune cells. Semin Immunol. 2025;77:101925.","journal-title":"Semin Immunol"},{"key":"3858_CR180","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","volume":"77","author":"H L\u00e4ubli","year":"2020","unstructured":"L\u00e4ubli H, Varki A. Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses. Cell Mol Life Sci. 2020;77:593\u2013605.","journal-title":"Cell Mol Life Sci"},{"key":"3858_CR181","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1172\/JCI120612","volume":"128","author":"MA Stanczak","year":"2018","unstructured":"Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Investig. 2018;128:4912\u201323.","journal-title":"J Clin Investig"},{"key":"3858_CR182","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/2326-6066.CIR-18-0505","volume":"7","author":"Q Haas","year":"2019","unstructured":"Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, et al. Siglec-9 regulates an effector memory CD8(+) T-cell subset that congregates in the melanoma tumor microenvironment. Cancer Immunol Res. 2019;7:707\u201318.","journal-title":"Cancer Immunol Res"},{"key":"3858_CR183","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nchembio.1388","volume":"10","author":"JE Hudak","year":"2014","unstructured":"Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 2014;10:69\u201375.","journal-title":"Nat Chem Biol"},{"key":"3858_CR184","doi-asserted-by":"publisher","first-page":"e180282.","DOI":"10.1172\/JCI180282","volume":"134","author":"RM Wen","year":"2024","unstructured":"Wen RM, Stark JC, Marti GEW, Fan Z, Lyu A, Garcia Marques FJ. Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer. J Clin Investig. 2024;134:e180282.","journal-title":"J Clin Investig"},{"key":"3858_CR185","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1172\/JCI65899","volume":"124","author":"C Jandus","year":"2014","unstructured":"Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, D\u00e9moulins T, et al. Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Investig. 2014;124:1810\u201320.","journal-title":"J Clin Investig"},{"key":"3858_CR186","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/ni.3552","volume":"17","author":"R Beatson","year":"2016","unstructured":"Beatson R, Tajadura-Ortega V, Achkova D, Picco G, Tsourouktsoglou TD, Klausing S, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17:1273\u201381.","journal-title":"Nat Immunol"},{"key":"3858_CR187","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00759-1","volume":"13","author":"N Zhang","year":"2025","unstructured":"Zhang N, Liu Q, Wang D, Wang X, Pan Z, Han B, et al. Multifaceted roles of Galectins: from carbohydrate binding to targeted cancer therapy. Biomark Res. 2025;13:49.","journal-title":"Biomark Res"},{"key":"3858_CR188","first-page":"88","volume":"2","author":"AH Ebrahim","year":"2014","unstructured":"Ebrahim AH, Alalawi Z, Mirandola L, Rakhshanda R, Dahlbeck S, Nguyen D, et al. Galectins in cancer: carcinogenesis, diagnosis and therapy. Ann Transl Med. 2014;2:88.","journal-title":"Ann Transl Med"},{"key":"3858_CR189","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrc1527","volume":"5","author":"FT Liu","year":"2005","unstructured":"Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5:29\u201341.","journal-title":"Nat Rev Cancer"},{"key":"3858_CR190","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41577-022-00829-7","volume":"23","author":"FT Liu","year":"2023","unstructured":"Liu FT, Stowell SR. The role of galectins in immunity and infection. Nat Rev Immunol. 2023;23:479\u201394.","journal-title":"Nat Rev Immunol"},{"key":"3858_CR191","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1535-6108(04)00024-8","volume":"5","author":"N Rubinstein","year":"2004","unstructured":"Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell. 2004;5:241\u201351.","journal-title":"Cancer Cell"},{"key":"3858_CR192","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1158\/0008-5472.CAN-10-4157","volume":"71","author":"A Banh","year":"2011","unstructured":"Banh A, Zhang J, Cao H, Bouley DM, Kwok S, Kong C, et al. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 2011;71:4423\u201331.","journal-title":"Cancer Res"},{"key":"3858_CR193","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/ni.1772","volume":"10","author":"JM Ilarregui","year":"2009","unstructured":"Ilarregui JM, Croci DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME, et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol. 2009;10:981\u201391.","journal-title":"Nat Immunol"},{"key":"3858_CR194","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.trecan.2023.11.009","volume":"10","author":"K Boelaars","year":"2024","unstructured":"Boelaars K, van Kooyk Y. Targeting myeloid cells for cancer immunotherapy: siglec-7\/9\/10\/15 and their ligands. Trends Cancer. 2024;10:230\u201341.","journal-title":"Trends Cancer"},{"key":"3858_CR195","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41573-020-00093-1","volume":"20","author":"BAH Smith","year":"2021","unstructured":"Smith BAH, Bertozzi CR. The clinical impact of glycobiology: targeting selectins, siglecs and mammalian glycans. Nat Rev Drug Discov. 2021;20:217\u201343.","journal-title":"Nat Rev Drug Discov"},{"key":"3858_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2025.104203","volume":"105","author":"JR Ellis","year":"2025","unstructured":"Ellis JR, Will E, Ogurtsova A, Engle LL, Taube JM, Sunshine JC. Siglec ligand immunohistochemistry reveals association with immune exclusion and survival. Lab Invest. 2025;105:104203.","journal-title":"Lab Invest"},{"key":"3858_CR197","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/0008-5472.CAN-12-1260","volume":"73","author":"DJ Laderach","year":"2013","unstructured":"Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res. 2013;73:86\u201396.","journal-title":"Cancer Res"},{"key":"3858_CR198","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1158\/1078-0432.CCR-18-0157","volume":"24","author":"TC Shih","year":"2018","unstructured":"Shih TC, Liu R, Wu CT, Li X, Xiao W, Deng X, et al. Targeting galectin-1 impairs castration-resistant prostate cancer progression and invasion. Clin Cancer Res. 2018;24:4319\u201331.","journal-title":"Clin Cancer Res"},{"key":"3858_CR199","doi-asserted-by":"publisher","first-page":"351.","DOI":"10.3390\/cancers17030351","volume":"17","author":"HC Wang","year":"2025","unstructured":"Wang HC, Gao AC, Xia R, Wu CT, Hsu SW, Chen CH. Inhibition of galectin-1 and androgen receptor axis enhances enzalutamide treatment in enzalutamide-resistant prostate cancer. Cancers. 2025;17:351.","journal-title":"Cancers"},{"key":"3858_CR200","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1372956","volume":"15","author":"HC Wang","year":"2024","unstructured":"Wang HC, Xia R, Chang WH, Hsu SW, Wu CT, Chen CH, et al. Improving cancer immunotherapy in prostate cancer by modulating T cell function through targeting galectin-1. Front Immunol. 2024;15:1372956.","journal-title":"Front Immunol"},{"key":"3858_CR201","doi-asserted-by":"publisher","first-page":"1398.","DOI":"10.3390\/biom11101398","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang Y, Wang HC, Zhao J, Wu MH, Shih TC. Immunosuppressive roles of galectin-1 in the tumor microenvironment. Biomolecules. 2021;11:1398.","journal-title":"Biomolecules"},{"key":"3858_CR202","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00345-012-0925-y","volume":"31","author":"JS Knapp","year":"2013","unstructured":"Knapp JS, Lokeshwar SD, Vogel U, Hennenlotter J, Schwentner C, Kramer MW, et al. Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence. World J Urol. 2013;31:351\u20138.","journal-title":"World J Urol"},{"key":"3858_CR203","first-page":"839","volume":"11","author":"J Gao","year":"2018","unstructured":"Gao J, Li T, Mo Z, Hu Y, Yi Q, He R, et al. Overexpression of the galectin-3 during tumor progression in prostate cancer and its clinical implications. Int J Clin Exp Pathol. 2018;11:839\u201346.","journal-title":"Int J Clin Exp Pathol"},{"key":"3858_CR204","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001535","volume":"8","author":"C Tiraboschi","year":"2020","unstructured":"Tiraboschi C, Gentilini L, Vel\u00e1zquez C, Corapi E, Jaworski FM, Garc\u00eda Garc\u00eda JD, et al. Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome. J Immunother Cancer. 2020;8:e001535.","journal-title":"J Immunother Cancer"},{"key":"3858_CR205","doi-asserted-by":"publisher","first-page":"542","DOI":"10.18632\/oncotarget.923","volume":"4","author":"V Balan","year":"2013","unstructured":"Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, et al. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 2013;4:542\u201349.","journal-title":"Oncotarget"},{"key":"3858_CR206","first-page":"1389","volume":"6","author":"I Iurisci","year":"2000","unstructured":"Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res. 2000;6:1389\u201393.","journal-title":"Clin Cancer Res"},{"key":"3858_CR207","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1158\/0008-5472.CAN-15-1793","volume":"76","author":"K Nakajima","year":"2016","unstructured":"Nakajima K, Kho DH, Yanagawa T, Harazono Y, Hogan V, Chen W, et al. Galectin-3 cleavage alters bone remodeling: different outcomes in breast and prostate cancer skeletal metastasis. Cancer Res. 2016;76:1391\u2013402.","journal-title":"Cancer Res"},{"key":"3858_CR208","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.neo.2014.09.005","volume":"16","author":"K Nakajima","year":"2014","unstructured":"Nakajima K, Kho DH, Yanagawa T, Harazono Y, Gao X, Hogan V, et al. Galectin-3 inhibits osteoblast differentiation through notch signaling. Neoplasia. 2014;16:939\u201349.","journal-title":"Neoplasia"},{"key":"3858_CR209","doi-asserted-by":"publisher","first-page":"44654","DOI":"10.18632\/oncotarget.17963","volume":"8","author":"LD Gentilini","year":"2017","unstructured":"Gentilini LD, Jaworski FM, Tiraboschi C, P\u00e9rez IG, Kotler ML, Chauchereau A, et al. Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer. Oncotarget. 2017;8:44654\u201368.","journal-title":"Oncotarget"},{"key":"3858_CR210","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.1158\/0008-5472.CAN-16-0641","volume":"76","author":"CH Tsai","year":"2016","unstructured":"Tsai CH, Tzeng SF, Chao TK, Tsai CY, Yang YC, Lee MT, et al. Metastatic progression of prostate cancer is mediated by autonomous binding of galectin-4-O-glycan to cancer cells. Cancer Res. 2016;76:5756\u201367.","journal-title":"Cancer Res"},{"key":"3858_CR211","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41573-023-00636-2","volume":"22","author":"KV Mari\u00f1o","year":"2023","unstructured":"Mari\u00f1o KV, Cagnoni AJ, Croci DO, Rabinovich GA. Targeting galectin-driven regulatory circuits in cancer and fibrosis. Nat Rev Drug Discov. 2023;22:295\u2013316.","journal-title":"Nat Rev Drug Discov"},{"key":"3858_CR212","doi-asserted-by":"publisher","first-page":"e20182041.","DOI":"10.1084\/jem.20182041","volume":"217","author":"MR Girotti","year":"2020","unstructured":"Girotti MR, Salatino M, Dalotto-Moreno T, Rabinovich GA. Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression. J Exp Med. 2020;217:e20182041.","journal-title":"J Exp Med"},{"key":"3858_CR213","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-019-0671-3","volume":"17","author":"NM Akella","year":"2019","unstructured":"Akella NM, Ciraku L, Reginato MJ. Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer. BMC Biol. 2019;17:52.","journal-title":"BMC Biol"},{"key":"3858_CR214","doi-asserted-by":"publisher","first-page":"53.","DOI":"10.3390\/cells7060053","volume":"7","author":"F Chiaradonna","year":"2018","unstructured":"Chiaradonna F, Ricciardiello F, Palorini R. The nutrient-sensing hexosamine biosynthetic pathway as the hub of cancer metabolic rewiring. Cells. 2018;7:53.","journal-title":"Cells"},{"key":"3858_CR215","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3892\/mmr.2014.2269","volume":"10","author":"Y Gu","year":"2014","unstructured":"Gu Y, Gao J, Han C, Zhang X, Liu H, Ma L, et al. O-GlcNAcylation is increased in prostate cancer tissues and enhances malignancy of prostate cancer cells. Mol Med Rep. 2014;10:897\u2013904.","journal-title":"Mol Med Rep"},{"key":"3858_CR216","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/pcan.2013.56","volume":"17","author":"T Kamigaito","year":"2014","unstructured":"Kamigaito T, Okaneya T, Kawakubo M, Shimojo H, Nishizawa O, Nakayama J. Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer Prostatic Dis. 2014;17:18\u201322.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3858_CR217","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1158\/0008-5472.CAN-13-0549","volume":"73","author":"HM Itkonen","year":"2013","unstructured":"Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, et al. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res. 2013;73:5277\u201387.","journal-title":"Cancer Res"},{"key":"3858_CR218","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1038\/onc.2014.307","volume":"34","author":"HM Itkonen","year":"2015","unstructured":"Itkonen HM, Engedal N, Babaie E, Luhr M, Guldvik IJ, Minner S, et al. UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. Oncogene. 2015;34:3744\u201350.","journal-title":"Oncogene"},{"key":"3858_CR219","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11612","volume":"7","author":"AK Kaushik","year":"2016","unstructured":"Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, et al. Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun. 2016;7:11612.","journal-title":"Nat Commun"},{"key":"3858_CR220","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41416-024-02762-z","volume":"131","author":"M Pujana-Vaquerizo","year":"2024","unstructured":"Pujana-Vaquerizo M, Bozal-Basterra L, Carracedo A. Metabolic adaptations in prostate cancer. Br J Cancer. 2024;131:1250\u201362.","journal-title":"Br J Cancer"},{"key":"3858_CR221","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.trecan.2020.04.002","volume":"6","author":"AF Costa","year":"2020","unstructured":"Costa AF, Campos D, Reis CA, Gomes C. Targeting glycosylation: a new road for cancer drug discovery. Trends Cancer. 2020;6:757\u201366.","journal-title":"Trends Cancer"},{"key":"3858_CR222","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1158\/1538-7445.AM2018-5551","volume":"78","author":"NM Okeley","year":"2018","unstructured":"Okeley NM, Heiser RA, Zeng W, Hengel SM, Wall J, Haughney PC, et al. SGN-2FF: A small-molecule inhibitor of fucosylation modulates immune cell activity in preclinical models and demonstrates pharmacodynamic activity in early phase 1 analysis. Cancer Res. 2018;78:5551.","journal-title":"Cancer Res"},{"key":"3858_CR223","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/onco.13911","volume":"26","author":"KT Do","year":"2021","unstructured":"Do KT, Chow LQM, Reckamp K, Sanborn RE, Burris H, Robert F, et al. First-in-human, first-in-class, phase I trial of the fucosylation inhibitor SGN-2FF in patients with advanced solid tumors. Oncologist. 2021;26:925\u2013e1918.","journal-title":"Oncologist"},{"key":"3858_CR224","doi-asserted-by":"publisher","first-page":"12139","DOI":"10.1039\/D2CC04275D","volume":"58","author":"E Rossing","year":"2022","unstructured":"Rossing E, Pijnenborg JFA, Boltje TJ. Chemical tools to track and perturb the expression of sialic acid and fucose monosaccharides. Chem Commun. 2022;58:12139\u201350.","journal-title":"Chem Commun"},{"key":"3858_CR225","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1002\/chem.202005359","volume":"27","author":"JFA Pijnenborg","year":"2021","unstructured":"Pijnenborg JFA, Visser EA, Noga M, Rossing E, Veizaj R, Lefeber DJ, et al. Cellular fucosylation inhibitors based on fluorinated fucose-1-phosphates*. Chemistry. 2021;27:4022\u201327.","journal-title":"Chemistry"},{"key":"3858_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27355-9","volume":"12","author":"JFA Pijnenborg","year":"2021","unstructured":"Pijnenborg JFA, Rossing E, Merx J, Noga MJ, Titulaer WHC, Eerden N, et al. Fluorinated rhamnosides inhibit cellular fucosylation. Nat Commun. 2021;12:7024.","journal-title":"Nat Commun"},{"key":"3858_CR227","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1021\/nn5061964","volume":"9","author":"C B\u00fcll","year":"2015","unstructured":"B\u00fcll C, Boltje TJ, van Dinther EA, Peters T, de Graaf AM, Leusen JH, et al. Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread. ACS Nano. 2015;9:733\u201345.","journal-title":"ACS Nano"},{"key":"3858_CR228","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1158\/0008-5472.CAN-17-3376","volume":"78","author":"C B\u00fcll","year":"2018","unstructured":"B\u00fcll C, Boltje TJ, Balneger N, Weischer SM, Wassink M, van Gemst JJ, et al. Sialic acid blockade suppresses tumor growth by enhancing T-cell-mediated tumor immunity. Cancer Res. 2018;78:3574\u201388.","journal-title":"Cancer Res"},{"key":"3858_CR229","doi-asserted-by":"publisher","first-page":"4248.","DOI":"10.3390\/cancers14174248","volume":"14","author":"J Munkley","year":"2022","unstructured":"Munkley J. Aberrant sialylation in cancer: therapeutic opportunities. Cancers. 2022;14:4248.","journal-title":"Cancers"},{"key":"3858_CR230","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1021\/acs.jmedchem.8b01757","volume":"62","author":"T Heise","year":"2019","unstructured":"Heise T, Pijnenborg JFA, B\u00fcll C, van Hilten N, Kers-Rebel ED, Balneger N, et al. Potent metabolic sialylation inhibitors based on C-5-modified fluorinated sialic acids. J Med Chem. 2019;62:1014\u201321.","journal-title":"J Med Chem"},{"key":"3858_CR231","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1021\/acschembio.1c00868","volume":"17","author":"SJ Moons","year":"2022","unstructured":"Moons SJ, Rossing E, Janssen M, Heise T, B\u00fcll C, Adema GJ, et al. Structure-activity relationship of metabolic sialic acid inhibitors and labeling reagents. ACS Chem Biol. 2022;17:590\u201397.","journal-title":"ACS Chem Biol"},{"key":"3858_CR232","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ccell.2017.05.012","volume":"31","author":"A Magalhaes","year":"2017","unstructured":"Magalhaes A, Duarte HO, Reis CA. Aberrant glycosylation in cancer: a novel molecular mechanism controlling metastasis. Cancer Cell. 2017;31:733\u201335.","journal-title":"Cancer Cell"},{"key":"3858_CR233","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbplus.2022.100108","volume":"16","author":"K Almahayni","year":"2022","unstructured":"Almahayni K, Spiekermann M, Fiore A, Yu G, Pedram K, Mockl L. Small molecule inhibitors of mammalian glycosylation. Matrix Biol. 2022;16:100108.","journal-title":"Matrix Biol"},{"key":"3858_CR234","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/14728222.2026.2619761","volume":"30","author":"Z Peng","year":"2026","unstructured":"Peng Z, Hodgson K, Orozco-Moreno M, Munkley J. Blocking glycan production by targeting GALNT7 for prostate cancer therapy. Expert Opin Ther Targets. 2026;30:87\u201392.","journal-title":"Expert Opin Ther Targets"},{"key":"3858_CR235","doi-asserted-by":"publisher","first-page":"e24051.","DOI":"10.7554\/eLife.24051","volume":"6","author":"L Song","year":"2017","unstructured":"Song L, Linstedt AD. Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels. Elife. 2017;6:e24051.","journal-title":"Elife"},{"key":"3858_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107492","volume":"149","author":"Y Lv","year":"2024","unstructured":"Lv Y, Zhang Z, Wang M, Wang Y, Chen M, Jia J, et al. Discovery of novel FUT8 inhibitors with promising affinity and in vivo efficacy for colorectal cancer therapy. Bioorg Chem. 2024;149:107492.","journal-title":"Bioorg Chem"},{"key":"3858_CR237","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202414682","volume":"63","author":"Y Manabe","year":"2024","unstructured":"Manabe Y, Takebe T, Kasahara S, Hizume K, Kabayama K, Kamada Y, et al. Development of a FUT8 inhibitor with cellular inhibitory properties. Angew Chem Int Ed Engl. 2024;63:e202414682.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3858_CR238","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202400088","volume":"19","author":"R Szabo","year":"2024","unstructured":"Szabo R, Dobie C, Montgomery AP, Steele H, Yu H, Skropeta D. Synthesis of \u03b1-hydroxy-1,2,3-triazole-linked sialyltransferase inhibitors and evaluation of selectivity towards ST3GAL1, ST6GAL1 and ST8SIA2. ChemMedChem. 2024;19:e202400088.","journal-title":"ChemMedChem"},{"key":"3858_CR239","doi-asserted-by":"publisher","first-page":"cwaf077.","DOI":"10.1093\/glycob\/cwaf077","volume":"20","author":"H Sousa","year":"2025","unstructured":"Sousa H, Ribeiro IAB, Falc\u00e3o M, Barreira DF, Barbosa M, Sharma S, et al. Short mucin-type O-glycans in cancer: biomarker and therapeutic potential amid analytical barriers. Glycobiology. 2025;20:cwaf077.","journal-title":"Glycobiology"},{"key":"3858_CR240","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ccell.2019.06.006","volume":"36","author":"S Mereiter","year":"2019","unstructured":"Mereiter S, Balmana M, Campos D, Gomes J, Reis CA. Glycosylation in the era of cancer-targeted therapy: where are we heading? Cancer Cell. 2019;36:6\u201316.","journal-title":"Cancer Cell"},{"key":"3858_CR241","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1466255","volume":"14","author":"R Abrantes","year":"2024","unstructured":"Abrantes R, Lopes J, Lopes D, Gomes J, Melo SA, Reis CA. Sialyl-Tn glycan epitope as a target for pancreatic cancer therapies. Front Oncol. 2024;14:1466255.","journal-title":"Front Oncol"},{"key":"3858_CR242","doi-asserted-by":"publisher","first-page":"1888.","DOI":"10.3390\/cancers17111888","volume":"17","author":"A Griffiths","year":"2025","unstructured":"Griffiths A, Udomjarumanee P, Georgescu AS, Barri M, Zinovkin DA, Pranjol MZI. The immunomodulatory role of galectin-1 in the tumour microenvironment and strategies for therapeutic applications. Cancers. 2025;17:1888.","journal-title":"Cancers"},{"key":"3858_CR243","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1021\/acsptsci.5c00178","volume":"8","author":"P Granger Joly de Boissel","year":"2025","unstructured":"Granger Joly de Boissel P, Nehm\u00e9 R, Fortier M, L\u00e9tourneau M, Gu\u00e9rin B, Dumulon-Perreault V, et al. Development and use of a galectin-1-specific nanobody for tumor imaging and elucidating the role of galectin\u20111 in cancer. ACS Pharm Transl Sci. 2025;8:2564\u201374.","journal-title":"ACS Pharm Transl Sci"},{"key":"3858_CR244","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s10020-025-01356-6","volume":"31","author":"P Sindrewicz-Goral","year":"2025","unstructured":"Sindrewicz-Goral P, Li X, Wang W, Adegbite O, Pang Y, Gledhill T, et al. Targeting galectin-3 in cancer by novel and unique inhibitors of non-carbohydrate origin. Mol Med. 2025;31:299.","journal-title":"Mol Med"},{"key":"3858_CR245","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj1270","volume":"14","author":"MA Stanczak","year":"2022","unstructured":"Stanczak MA, Rodrigues Mantuano N, Kirchhammer N, Sanin DE, Jacob F, Coelho R, et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages, allowing effective immune checkpoint blockade. Sci Transl Med. 2022;14:eabj1270.","journal-title":"Sci Transl Med"},{"key":"3858_CR246","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000541881","volume":"103","author":"R Novysedlak","year":"2025","unstructured":"Novysedlak R, Guney M, Al Khouri M, Bartolini R, Koumbas Foley L, Benesova I, et al. The immune microenvironment in prostate cancer: a comprehensive review. Oncology. 2025;103:521\u201345.","journal-title":"Oncology"},{"key":"3858_CR247","doi-asserted-by":"publisher","first-page":"1797299","DOI":"10.3389\/fimmu.2026.1797299","volume":"17","author":"J Xue","year":"2026","unstructured":"Xue J, Liao K, Zhang M. Tumor-immune spatiotemporal co-evolution as a paradigm for overcoming therapy resistance in advanced prostate cancer. Front Immunol. 2026;17:1797299.","journal-title":"Front Immunol"},{"key":"3858_CR248","doi-asserted-by":"publisher","first-page":"1702.","DOI":"10.3390\/cancers14071702","volume":"14","author":"SM Mutuku","year":"2022","unstructured":"Mutuku SM, Spotbeen X, Trim PJ, Snel MF, Butler LM, Swinnen JV. Unravelling prostate cancer heterogeneity using spatial approaches to lipidomics and transcriptomics. Cancers. 2022;14:1702.","journal-title":"Cancers"},{"key":"3858_CR249","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00216-024-05178-z","volume":"416","author":"JXM Truong","year":"2024","unstructured":"Truong JXM, Rao SR, Ryan FJ, Lynn DJ, Snel MF, Butler LM, et al. Spatial MS multiomics on clinical prostate cancer tissues. Anal Bioanal Chem. 2024;416:1745\u201357.","journal-title":"Anal Bioanal Chem"},{"key":"3858_CR250","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ccell.2025.11.006","volume":"44","author":"H Piyadasa","year":"2026","unstructured":"Piyadasa H, Oberlton B, Ribi M, Leow K, Ranek JS, Averbukh I, et al. Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence. Cancer Cell. 2026;44:112\u201328.e116.","journal-title":"Cancer Cell"},{"key":"3858_CR251","doi-asserted-by":"publisher","first-page":"cwaf010.","DOI":"10.1093\/glycob\/cwaf010","volume":"35","author":"KL Kapp","year":"2025","unstructured":"Kapp KL, Garcia-Marques F, Totten SM, Bermudez A, Tanimoto C, Brooks JD. Intact glycopeptide analysis of human prostate tissue reveals site-specific heterogeneity of protein glycosylation in prostate cancer. Glycobiology. 2025;35:cwaf010.","journal-title":"Glycobiology"},{"key":"3858_CR252","doi-asserted-by":"publisher","DOI":"10.1002\/jms.5034","volume":"59","author":"SA Malaker","year":"2024","unstructured":"Malaker SA. Glycoproteomics: charting new territory in mass spectrometry and glycobiology. J Mass Spectrom. 2024;59:e5034.","journal-title":"J Mass Spectrom"},{"key":"3858_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2025.101085","volume":"24","author":"K Kothlow","year":"2025","unstructured":"Kothlow K, Schramm HM, Markuson KA, Russell JH, Sutherland E, Veth TS, et al. Extracting informative glycan-specific ions from glycopeptide MS\/MS spectra with glycounter. Mol Cell Proteom. 2025;24:101085.","journal-title":"Mol Cell Proteom"},{"key":"3858_CR254","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/s41594-025-01485-w","volume":"32","author":"CM Potel","year":"2025","unstructured":"Potel CM, Burtscher ML, Garrido-Rodriguez M, Brauer-Nikonow A, Becher I, Le Sueur C, et al. Uncovering protein glycosylation dynamics and heterogeneity using deep quantitative glycoprofiling (DQGlyco). Nat Struct Mol Biol. 2025;32:1111\u201326.","journal-title":"Nat Struct Mol Biol"},{"key":"3858_CR255","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00216-025-05780-9","volume":"417","author":"RA Hogan","year":"2025","unstructured":"Hogan RA, Pepi LE, Riley NM, Chalkley RJ. Comparative analysis of glycoproteomic software using a tailored glycan database. Anal Bioanal Chem. 2025;417:1985\u20132001.","journal-title":"Anal Bioanal Chem"},{"key":"3858_CR256","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31062-4","volume":"13","author":"SA Malaker","year":"2022","unstructured":"Malaker SA, Riley NM, Shon DJ, Pedram K, Krishnan V, Dorigo O, et al. Revealing the human mucinome. Nat Commun. 2022;13:3542.","journal-title":"Nat Commun"},{"key":"3858_CR257","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41587-023-01840-6","volume":"42","author":"K Pedram","year":"2024","unstructured":"Pedram K, Shon DJ, Tender GS, Mantuano NR, Northey JJ, Metcalf KJ, et al. Design of a mucin-selective protease for targeted degradation of cancer-associated mucins. Nat Biotechnol. 2024;42:597\u2013607.","journal-title":"Nat Biotechnol"},{"key":"3858_CR258","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1016\/j.cell.2021.04.023","volume":"184","author":"RA Flynn","year":"2021","unstructured":"Flynn RA, Pedram K, Malaker SA, Batista PJ, Smith BAH, Johnson AG, et al. Small RNAs are modified with N-glycans and displayed on the surface of living cells. Cell. 2021;184:3109\u201324.e3122.","journal-title":"Cell"},{"key":"3858_CR259","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1016\/j.cell.2024.07.044","volume":"187","author":"Y Xie","year":"2024","unstructured":"Xie Y, Chai P, Till NA, Hemberger H, Lebedenko CG, Porat J, et al. The modified RNA base acp(3)U is an attachment site for N-glycans in glycoRNA. Cell. 2024;187:5228\u201337.e5212.","journal-title":"Cell"},{"key":"3858_CR260","doi-asserted-by":"publisher","first-page":"16906","DOI":"10.1021\/acs.analchem.5c02197","volume":"97","author":"J Li","year":"2025","unstructured":"Li J, Wang L, Deng J, Miao X, Yang X, Zhou Y, et al. O-Glycosylated RNA identification and prediction by solid-phase chemoenzymatic TnORNA method and PONglyRNA tool. Anal Chem. 2025;97:16906\u2013915.","journal-title":"Anal Chem"},{"key":"3858_CR261","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.cell.2023.12.033","volume":"187","author":"N Zhang","year":"2024","unstructured":"Zhang N, Tang W, Torres L, Wang X, Ajaj Y, Zhu L, et al. Cell surface RNAs control neutrophil recruitment. Cell. 2024;187:846\u201360.e817.","journal-title":"Cell"},{"key":"3858_CR262","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41586-025-10052-8","volume":"651","author":"P Chai","year":"2026","unstructured":"Chai P, Kheiri S, Kuo A, Shah J, Kageler L, Ge R, et al. GlycoRNA complexed with heparan sulfate regulates VEGF-A signalling. Nature. 2026;651:808\u201318.","journal-title":"Nature"},{"key":"3858_CR263","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1158\/1538-7445.AM2025-2797","volume":"85","author":"E Jones","year":"2025","unstructured":"Jones E, McGuire S, Moen S, Kerscher AE. Abstract 2797: N-linked and O-linked glycosylated RNA enrichment in human prostate cell lines with low\/no malignancy. Cancer Res. 2025;85:2797\u201397.","journal-title":"Cancer Res"},{"key":"3858_CR264","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1158\/1538-7445.AM2024-2984","volume":"84","author":"S McGuire","year":"2024","unstructured":"McGuire S, Jones E, Moen S, Esquela-Kerscher A. Abstract 2984: prostate cancer associated glycosylated RNAs: who are you and where are you hiding. Cancer Res. 2024;84:2984.","journal-title":"Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03858-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:02:25Z","timestamp":1782770545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03858-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":264,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2026,7,21]]}},"alternative-id":["3858"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03858-x","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}